329 related articles for article (PubMed ID: 25848244)
21. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
22. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Gupta V; Singh D
Expert Rev Respir Med; 2012 Dec; 6(6):581-8. PubMed ID: 23234445
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
24. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Stone LE; Skelley JW; Kyle JA; Elmore LK
Am J Health Syst Pharm; 2014 Mar; 71(5):386-93. PubMed ID: 24534593
[TBL] [Abstract][Full Text] [Related]
25. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
Watz H; Troosters T; Beeh KM; Garcia-Aymerich J; Paggiaro P; Molins E; Notari M; Zapata A; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2017; 12():2545-2558. PubMed ID: 28883722
[TBL] [Abstract][Full Text] [Related]
26. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
Manoharan A; Morrison AE; Lipworth BJ
Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
[TBL] [Abstract][Full Text] [Related]
27. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
[TBL] [Abstract][Full Text] [Related]
28. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.
Woods JA; Nealy KL; Barrons RW
Ann Pharmacother; 2013; 47(7-8):1017-28. PubMed ID: 23737515
[TBL] [Abstract][Full Text] [Related]
29. Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.
D'Urzo AD; Kardos P; Wiseman R
Int J Chron Obstruct Pulmon Dis; 2018; 13():1089-1104. PubMed ID: 29670345
[TBL] [Abstract][Full Text] [Related]
30. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
Wise RA; Chapman KR; Scirica BM; Bhatt DL; Daoud SZ; Zetterstrand S; Reisner C; Gil EG
JAMA; 2019 May; 321(17):1693-1701. PubMed ID: 31063575
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
32. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Malerba M; Radaeli A; Santini G; Morjaria J; Mores N; Mondino C; Macis G; Montuschi P
Expert Opin Drug Discov; 2018 Jun; 13(6):563-577. PubMed ID: 29616842
[TBL] [Abstract][Full Text] [Related]
33. A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study.
Kostikas K; Vassilakopoulos TI; Tzanakis N; Konstantinidis AK; Kosmas EN; Papiris S; Steiropoulos P; Manali ED; Michaelides SA; Daskos G
Int J Chron Obstruct Pulmon Dis; 2020; 15():515-526. PubMed ID: 32184588
[TBL] [Abstract][Full Text] [Related]
34. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.
Chapman KR; Wise RA; Scirica BM; Bhatt DL; Daoud SZ; Lythgoe D; Gil EG
Respir Res; 2021 Oct; 22(1):272. PubMed ID: 34686204
[TBL] [Abstract][Full Text] [Related]
35. Aclidinium: in chronic obstructive pulmonary disease.
Frampton JE
Drugs; 2012 Oct; 72(15):1999-2011. PubMed ID: 23046206
[TBL] [Abstract][Full Text] [Related]
36. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
[TBL] [Abstract][Full Text] [Related]
37. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
[TBL] [Abstract][Full Text] [Related]
38. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
Santus P; Radovanovic D; Di Marco F; Raccanelli R; Valenti V; Centanni S
Pulm Pharmacol Ther; 2015 Dec; 35():42-9. PubMed ID: 26549785
[TBL] [Abstract][Full Text] [Related]
39. Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.
Wedzicha JA; Agusti A; Donaldson G; Chuecos F; Lamarca R; Garcia Gil E
COPD; 2016 Dec; 13(6):669-676. PubMed ID: 27159613
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.
Wise RA; Scirica BM; Bhatt DL; Daoud SZ; Chuecos F; Garcia Gil E; Chapman KR
Adv Ther; 2021 Oct; 38(10):5381-5397. PubMed ID: 34528220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
